Advancements in the identification of adducts of drug-human serum albumin
10.16438/j.0513-4870.2023-0922
- VernacularTitle:药物与人血清白蛋白共价加合物的鉴定研究进展
- Author:
Xiao-yun LIU
1
;
Xing-xing DIAO
2
;
Da-fang ZHONG
2
Author Information
1. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; Betta Pharmaceuticals Co., Ltd., Hangzhou 311100, China
2. Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
- Publication Type:Research Article
- Keywords:
human serum albumin;
covalent adduct;
adductomics;
adverse drug reaction;
pharmacokinetics
- From:
Acta Pharmaceutica Sinica
2024;59(4):886-898
- CountryChina
- Language:Chinese
-
Abstract:
The covalent binding of drugs and their metabolites to proteins forms drug-protein adducts, which may cause adverse reactions in the body. The development of adductomics technology is helpful for the identification of covalent adducts between drugs and human plasma proteins. For many drugs, such as beta-lactam antibiotics, acyl glucuronides, covalent tyrosine kinases inhibitors, and reactive metabolites, human serum albumin (HSA) is a potential target and biomarker for the formation of drug-protein adducts. In this review, we will describe the relevant technical advances, describe the methods for the identification of covalent adducts of drugs and HSA, define the chemical reactions that form adducts, and preliminarily explore the role of drug-HSA adducts in adverse drug reactions and the potential effect on pharmacokinetics.
